ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS

Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson
Médium: Artigo
Jazyk:Russo
Vydáno: «FIRMA «SILICEA» LLC 2011-04-01
Edice:Российский кардиологический журнал
Témata:
moderate to severe essential hypertension
olmesartan medoxomil
antihypertensive efficacy
safety
24-hour ambulatory blood pressure monitoring
On-line přístup:https://russjcardiol.elpub.ru/jour/article/view/1155
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky